...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
【24h】

Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.

机译：初次接受抗逆转录病毒治疗的患者中的去羟肌苷，拉米夫定和依非韦伦的长期评估：三年随访。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to evaluate the long-term efficacy and safety of didadosine (ddI), lamivudine (3TC), and efavirenz (EFV). This was a follow-up to the VESD study, a 12-month open-label, observational, multicenter study of adult patients with HIV infection who started antiretroviral treatment with the ddI-3TC-EFV once-daily regimen. Of the 167 patients originally included, 106 patients remained on the same triple therapy at the end of the study (1 year), and they were offered an extra 24 months of follow-up; 96 were enrolled in this study (VESD-2). Seventy patients out of the initial cohort were still on the same regimen at month 36, with 97% of them with plasma viral load <50 copies /ml. An intention-to-treat analysis showed that the percentage of patients with plasma viral load <50 copies/ml was 73% at 36 months. CD4 cell counts increased 344 cells/microl over the 36 months. Safety and tolerance were good with no unexpected long-term toxicity. After 3 years of treatment with ddI-3TC-EFV, morethan 40% of the patients were still receiving the initial antiretroviral therapy with sustained, durable immunovirological benefit and good acceptance. Long-term toxicity and virological failure were low.
机译：这项研究的目的是评估去氧肌苷（ddI），拉米夫定（3TC）和依非韦伦（EFV）的长期疗效和安全性。这是VESD研究的一项后续研究，该研究是一项为期12个月的开放标签，观察性，多中心研究，研究对象为每天开始使用ddI-3TC-EFV进行抗逆转录病毒治疗的成年HIV感染患者。在最初纳入的167例患者中，有106例患者在研究结束时（1年）仍接受相同的三联疗法，并且接受了额外的24个月随访;本研究共纳入96例（VESD-2）。最初队列中的70名患者在第36个月时仍采用相同的治疗方案，其中97％的血浆病毒载量小于50拷贝/ ml。治疗意向分析显示，血浆病毒载量<50拷贝/ ml的患者在36个月时的百分比为73％。在36个月中，CD4细胞计数增加了344细胞/微升。安全性和耐受性良好，没有意外的长期毒性。用ddI-3TC-EFV治疗3年后，超过40％的患者仍在接受初始抗逆转录病毒疗法，具有持续，持久的免疫病毒学益处，并被良好接受。长期毒性和病毒学失败率低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号